RxDoctor Payments Data

Kyle Bechaz, MD

Geriatric Psychiatry · Los Angeles, CANPI 1497042287

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 24.9% of the total. 2025 is the largest year on record at $515, 2.5 times the $209 reported in 2019.

$1,156in general payments, 2019–2025

Across 48 payments — averaging $24.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$288
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$184
  • GE HealthCare$180
  • Lundbeck LLC$140
  • Otsuka America Pharmaceutical, Inc.$94
  • Takeda Pharmaceuticals U.S.A., Inc.$85
  • plus $186 from 5 others

What the payments were for

  • Food & beverage$1,156100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,156 in reported general payments places this provider in the 80th percentile of 46 geriatric psychiatry providers in California.

See all geriatric psychiatry providers in California

Medicare billing

Part B allowed, 2024
$42,488
Medicare patients
32
Services billed
445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole15$19,743
Invega SustennaPaliperidone Palmitate12$9,832
Clozapine12$930
Mirtazapine17$766
Escitalopram Oxalate29$505
Bupropion XlBupropion Hcl23$421
Duloxetine Hcl37$407
Trazodone Hcl43$406
Fluoxetine Hcl20$400
Sertraline Hcl43$317
Lamotrigine51$263
Fluvoxamine Maleate11$256
Clonazepam48$216
Alprazolam34$215
Zolpidem Tartrate19$201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$94$19,74315 claims
Johnson & JohnsonInvega Sustenna$75$9,83212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 46 geriatric psychiatry providers in California.

Other geriatric psychiatry in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →